Two experiments were conducted to evaluate the effects of a high concentrate, subcutaneous (s.c.) PGF2α (Prostaglandin F2α) compared with a conventionally concentrated, intramuscular (i.m.) PGF2α in estrus synchronization protocols for heifers. No differences were detected in estrus response or pregnancy rates to artificial insemination (PR/AI) between treatments. (P = 0.40) between CONTROL and HiCON treatments (82 vs. 87 ± 4%). Furthermore, PR/AI were similar (P = 0.62) between CONTROL and HiCON treatments (60 vs. 65 ± 5%). We conclude that the 2 concentrations and corresponding routes of administration of PGF2α were similar in efficacy at synchronizing estrus in beef heifers.
Introduction
The beef industry regularly incurs economic losses due to carcass lesions resulting from improper injection technique (Pratt, 2004) . Intramuscular injections cause muscle trauma which results in an increase in connective tissue around the site during wound healing; therefore, this tissue damage negatively impacts beef tenderness (Boleman et al., 1998) and consumer acceptability of beef (Fajt et al., 2011) . The Beef Quality Assurance program advises producers to use a s.c. route of administration when possible to improve tenderness. Subcutaneous administration may reduce the occurrence of blemishes on beef carcasses (Powell, 2013) , improve tenderness (Griffin et al., 1998) , and reduce the income lost per head at slaughter (Hilton, 2004) .
A high concentrate PGF2α product, Lutalyse HighCon, was recently been approved for use by the United States Food and Drug Administration. According to label directions, Lutalyse HighCon may be administered by i.m. or s.c. injection in bovine females. To date, no research has been conducted to determine the effectiveness of this product in estrus synchronization protocols for beef heifers. Therefore, this study was performed to evaluate the efficacy of the high concentrate PGF2α product, Lutalyse HighCon, by determining its effectiveness in estrus response and pregnancy rates in beef heifers.
Materials and Methods

Experiment 1
This study was conducted during the summer of 2016. Angus-based crossbred, yearling heifers (n = 869; 895 ± 4 lb BW) were enrolled at 8 locations in 2 states (South Dakota and North Dakota). All heifers were exposed to the 7-d CO-Synch + CIDR protocol. On d -7, heifers received a 2-mL i.m. injection of GnRH and a CIDR insert containing 1.38 g of progesterone. On d 0, at CIDR removal, estrus detection patches were applied, and heifers were randomly assigned to receive 1 of 2 PGF2α treatments. Heifers assigned to the CONTROL treatment (n = 434) received a 5-mL i.m. injection of Lutalyse (5 mg of dinoprost tromethamine/mL), whereas those assigned to the HiCON treatment (n = 435) received a 2-mL s.c. injection of Lutalyse HighCon (12.5 mg of dinoprost tromethamine/mL). All heifers received a 100-μg injection of GnRH and were inseminated 54 ± 2 h after CIDR removal.
Estrus detection patches were utilized for estrus detection between CIDR removal and TAI. Heifers were considered to be in estrus when at least 50% of the rub-off coating was removed from the patch, or when the patch was absent. No less than 10 d after TAI, heifers were exposed to bulls for the remainder of the breeding season at 6 locations. Transrectal ultrasonography was performed between d 35 and 55 after TAI to determine PR/AI. Final pregnancy rates were determined by transrectal ultrasonography at least 35 d after the end of the breeding season.
Experiment 2
Yearling, Angus-based crossbred heifers (n = 190) were managed at 2 locations. Heifers at location 1 (n = 100; 750 ± 7 lb BW; L1) were managed at the West Central Research and Extension Center near North Platte, NE. Each heifer was offered a ration consisting of 14 lb grass hay, 8 lb wet corn gluten feed, and 1 lb of 1 of 2 mineral supplements. Heifers were synchronized using a melengestrol acetate (MGA) -PGF2α protocol. Heifers were offered 0.5 mg of MGA pellets in their diet per d from d 1 to 14. On d 33, heifers were blocked by previous treatments and assigned to either CONTROL (n = 50) or HiCON (n = 50) treatment. An estrus detection patch was applied concurrently with the PGF2α injection. All heifers were managed together and continuously observed for estrus from d 33 to 39. Heifers were considered to be expressing estrus when at least 50% of the rub-off coating was removed from the patch or when the patch was absent. Heifers were AI 12 h after estrus was detected. Heifers not detected in estrus between d 33 and 39 (n = 16) were given an injection of Lutalyse HighCon and placed with 2 bulls for natural service exposure. Heifers exposed to AI were placed in a separate pasture for 10 d before being placed with those not detected in estrus. Heifers remained with bulls for a 60 d breeding season at a ratio of 1:50. Pregnancy rates to AI and final pregnancy rates were diagnosed via transrectal ultrasonography (Aloka, Hitachi Aloka Medical America Inc., Wallingford, CT) 51 and 127 d after the initial PGF2α injection, respectively.
A second group of yearling, Angus-based crossbred heifers were managed at the Kelly Ranch near Sutherland, NE (n = 90; 719 ± 9 lb BW; location 2, L2), and were offered a ration containing 1.3 lb wet distillers grains, 5.3 lb grass hay, 7.1 lb corn silage, and 0.4 lb balancer pellets. Heifers were synchronized with the MGA-PGF2α protocol as previously described for L1 and assigned randomly to receive CONTROL (n = 45) or HiCON (n = 45) treatment.
Heifers were observed for estrus continuously from d 33 to 36. Heifers detected in estrus were AI approximately 12 h later. Heifers not expressing estrus by 96 h (n = 14) were administered 2 ml of GnRH, and TAI. Ten d following AI, 2 bulls were placed with heifers at a ratio of 1:45 during a 40 d breeding season. Pregnancy rates to AI were diagnosed via transrectal ultrasonography 57 d after the initial PGF2α injection, and BW was concurrently recorded. A final pregnancy diagnosis was performed 50 d after the initial pregnancy diagnosis on heifers not diagnosed pregnant to AI, and BW was simultaneously recorded.
All data was analyzed as a completely randomized design using the GLIMMIX procedure of SAS (SAS Institute, Inc., Cary, N.C) with heifer as the experimental unit.
Results
Experiment 1
Estrus expression between d 0 and TAI did not differ between CONTROL and HiCON treatments (P = 0.68); however, estrus expression differed among locations (P<0.01) and ranged from 36 to 65%. No treatment × location interaction was detected (P = 0.37). Pregnancy rate to TAI did not differ between CONTROL and HiCON treatments (P = 0.65); however, there was an effect of location (P<0.01) on PR/AI, which ranged from 38 to 61%. No treatment × location interaction was detected (P = 0.18). At the conclusion of the breeding season, final pregnancy rates did not differ between CONTROL and HiCON treatments (P = 0.95). Final pregnancy rates differed (P<0.01) among location, and ranged from 78 to 98%.
Experiment 2
The percentage of heifers detected in estrus was similar between CONTROL and HiCON treatments at ≤ 60 h (P = 0.15), at ≤ 72 h (P = 0.51), and at 72 h (P = 0.27). There was a tendency (P<0.08) for a location effect at ≤ 60 h and ≤ 72 h. The total percentage of heifers observed in estrus throughout the detection period was also similar between treatment groups (P = 0.40). A treatment × location interaction (P = 0.03) was detected for PR/AI between L1 (44 vs. 64 ± 7%, CONTROL vs. HiCON) and L2 (73 vs. 62 ± 7%, CONTROL vs. HiCON). Final pregnancy rates were similar between treatments (P = 0.11) and did not differ (P = 0.96) by location. 3.8 0.68 1 All heifers were estrus synchronized using the 7-d CO-Synch + controlled internal drug release (CIDR) protocol. Heifers were randomly assigned to receive 1 of 2 prostaglandin F2α (PGF2α) treatments at CIDR removal. Heifers assigned to the CONTROL treatment (n = 417) received a 5-mL i.m. injection of Lutalyse, whereas those assigned to the HiCON treatment (n = 424) received a 2-mL s.c. injection of Lutalyse HighCon. w -z Percentages within column for location differ (P≤0.05). Table 2 . Pregnancy rates to fixed-time artificial insemination in heifers after receiving conventional or high concentrate PGF2α (Exp. 1) Treatment 195/434 (44.9) 183/435 (42.1) 3.8 0.65 1 All heifers were estrus synchronized using the 7-d CO-Synch + controlled internal drug release protocol (CIDR). Heifers were randomly assigned to receive 1 of 2 prostaglandin F2α (PGF2α) treatments at CIDR removal. Heifers assigned to the CONTROL treatment (n = 417) received a 5-mL i.m. injection of Lutalyse, whereas those assigned to the HiCON treatment (n = 424) received a 2-mL s.c. injection of Lutalyse HighCon. Pregnancy rate to TAI was recorded between d 35 and 55 after TAI. x -z Percentages within column for location differ (P≤0.05). 
